This article is available to subscribers. Subscribe now. Already have an account? Sign in

Perspective

Federal Right-to-Try Legislation — Threatening the FDA’s Public Health Mission

List of authors.
  • Steven Joffe, M.D., M.P.H.,
  • and Holly Fernandez Lynch, J.D., M.B.E.

A bill passed by the Senate would sharply curtail the FDA’s oversight of access to investigational drugs. Although its impact would probably be limited, the motivation behind it threatens to weaken the FDA’s ability to pursue its public health mission.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available at NEJM.org.

This article was published on January 10, 2018, at NEJM.org.

Author Affiliations

From the Department of Medical Ethics and Health Policy, Perelman School of Medicine, and the Leonard Davis Institute of Health Economics, University of Pennsylvania (S.J., H.F.L.), and the Children’s Hospital of Philadelphia (S.J.) — all in Philadelphia.

Print Subscriber? Activate your online access.